Quarter
Charts

Ovid Therapeutics Inc.

OVID

CIK 0001636651 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$718K
Gross Profit
$718K

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -33.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 8.97 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.06x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    100Op Margin -9487.1% · trend +4110.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$0
investment in PP&E
Stock-based comp (TTM)
$5M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$151M
everything owned
Total liabilities
$20M
everything owed
Stockholders' equity
$131M
shareholder claim

Recent performance · 41 quarters

Revenue
$718K
Net Income↑+13.2% +$2M
$-12M
Free Cash Flow↑+100.0% +$22K
$0
Operating Margin↓-1842.0pts
-9487.1%

Drill down

OVID Sankey

See Ovid Therapeutics Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

OVID Charts

41 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

OVID Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics